Skip to Content

ABL1 Kinase Domain Mutation Analysis

Sequencing

Indication

- .To evaluate the basis for resistance (primary or acquired) to tyrosine kinase inhibitors (TKIs) in patients with Philadelphia-chromosome positive leukemias such as CML and B-ALL

- Progression to accelerated phase or blast phase in CML patients.

Methodology

The presence of point mutations in the ABL1 kinase domain of the BCR-ABL1 fusion gene (codons 221-500) is assessed by direct Sanger sequencing of the BCR-ABL1 fusion transcripts following nested PCR.

Test Parameters

The result will include the codon number, amino acid changes and relative abundance of the mutation(s) found. This test will detect mutated transcript that comprise at least 10% of total BCR-ABL1 fusion transcripts in sample.

Turnaround Time

10 days

Sample Requirements

  • 10 mls peripheral blood (PB) in purple top tube (EDTA Vacutainer), sent on wet ice

    or
  • 2-5 ml of bone marrow aspirate (BM), sent on wet ice

    or
  • 20 µg of purified RNA, sent on dry ice

    or
  • 10 µg of cDNA, sent on dry ice

CPT Codes

81403

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center